ArticleBJUI compass2026
Are template prostate biopsies still required in patients with high-risk PI-RADS lesions? A retrospective study of 470 patients.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To determine the incremental diagnostic yield of systematic template sampling during transperineal prostate biopsy (TPPB) in biopsy-naïve men and to identify patient subgroups where systematic biopsy might be safely omitted. Patients and Methods: We retrospectively analysed 470 consecutive biopsy-naïve men with PI-RADS 3-5 lesions on multiparametric MRI who underwent combined MRI-targeted and systematic template TPPB between January 2022 and May 2026 at a single institution. Clinically significant prostate cancer (csPCa) was defined as ISUP grade group 2 or higher. The primary outcome was csPCa detected on template biopsy in men with non-significant disease (ISUP < 2) on targeted biopsy. Results: Overall, csPCa was detected in 356/470 men (75.7%). Systematic template biopsy identified csPCa missed by targeted biopsy in 10/470 men (2.1%, 95% CI 1.0%-3.9%), representing 2.8% of all csPCa diagnoses. Smaller index lesion size on MRI was the only statistically significant predictor of csPCa missed by targeted biopsy (OR 0.50 per 5 mm increase, 95% CI 0.28-0.90, Conclusions: In this biopsy-naïve cohort of men undergoing combined MRI-targeted and template TPPB, systematic template biopsy provided a small incremental diagnostic yield for csPCa (2.1%) overall, with no added value in men with PI-RADS 5 lesions and a PSAD > 0.20 ng/mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.